Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
{{output}}
Background & aims: In the randomized, double-blind, phase 3 KEYNOTE-966 trial, pembrolizumab plus gemcitabine and cisplatin demonstrated a significant improvement in overall survival as first-line therapy for advanced biliary tra... ...
